Evidence map›Paper›PMID 26341731›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2015

Cannabidiol as a Potential Treatment for Anxiety Disorders.

Esther M Blessing, Maria M Steenkamp, Jorge Manzanares, Charles R Marmar

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05023759 (Anxiety Symptoms in Relation to Use of Hemp-Derived, Full Spectrum Cannabidiol), which is not on this map. Cited by 286 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
286citing papers in PubMed, 6 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05023759 completednot on this mapstarted 2020, after this paper: background citation

Anxiety Symptoms in Relation to Use of Hemp-Derived, Full Spectrum Cannabidiol (CBD): a Cohort Study

TypeobservationalSponsorFormula30A LLCRan2020 to 2020Enrolled30ConditionsGeneralized Anxiety DisorderArmsFormula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
3 · Its place in the literature

Who cites it

286 citing papers in PubMed, 6 syntheses or guidelines pooled it, 668 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

226 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Esther M BlessingNew York University School of Medicine, New York, NY, USA. esther.blessing@nyumc.org.
Maria M SteenkampNew York University School of Medicine, New York, NY, USA.
Jorge ManzanaresNew York University School of Medicine, New York, NY, USA.
Charles R MarmarNew York University School of Medicine, New York, NY, USA.
New York University · USInstituto de Neurociencias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.

Indexed as

AnimalsAnti-Anxiety AgentsAnxiety DisordersCannabidiolHumansAnti-Anxiety AgentsCannabidiolAnxietyCannabidiolEndocannabinoidsGeneralized anxiety disorderPost-traumatic stress disorder

Identifiers

PMID26341731
PMCPMC4604171
OpenAlexW1246635139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.